Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 13/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776969 | 1.00 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3767664 | 0.98 | HTR4 (0.52) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3767662 | 0.98 | HTR4 (0.52) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3883676 | 0.90 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3883680 | 0.90 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3768023 | 0.90 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3883684 | 0.90 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3768025 | 0.90 | HTR4 (0.51) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL3844694 | 0.89 | HTR4 (0.56) | HTR4TMEM97SIGMAR1HTR3A | |
| SCHEMBL8258931 | 0.89 | HTR4 (0.56) | HTR4TMEM97SIGMAR1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851467-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-12-14 | — | — | US | claimed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | claimed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | claimed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | claimed |
| US-7851467-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1960396-B1 | CARBAMATE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | disclosed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | HTR4 1/4885TMEM97 827/4885SIGMAR1 219/4885 |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR2B | HTR4 1/4885TMEM97 827/4885SIGMAR1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.